Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
27 Julho 2022 - 5:30PM
AMF REGULATED
INFORMATIONMontrouge, France, July 27, 2022
Half-Year Report on the DBV Technologies
Liquidity Contract with
ODDO BHF
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, today issued the Half-Year report on its
liquidity contract with ODDO BHF.
As of June 30, 2022, the following assets
appeared on the liquidity account:
- 106,287 DBV Technologies
shares;
- € 430,854.35.
Upon signing the liquidity contract in July
2018, the following resources appeared on the liquidity
account:
- 41,159 DBV Technologies ordinary
shares;
- € 432,367.25.
Number of transactions executed during the first
half-year of 2022:
Over the same period, the volumes traded
represented:
- 345,064 DBV Technologies ordinary
shares purchased for €1,056,560.18
- 392,408 DBV Technologies ordinary
shares sold for €1,311,871.05
About DBV TechnologiesDBV
Technologies is developing Viaskin™, an investigational proprietary
technology platform with broad potential applications in
immunotherapy. Viaskin is based on epicutaneous immunotherapy, or
EPIT™, and is DBV Technologies’ method of delivering biologically
active compounds to the immune system through intact skin. With
this new class of non-invasive product candidates, the Company is
dedicated to safely transforming the care of food allergic
patients. DBV Technologies’ food allergies programs include ongoing
clinical trials of Viaskin Peanut. DBV Technologies has global
headquarters in Montrouge, France, and North American operations in
Basking Ridge, NJ. The Company’s ordinary shares are traded on
segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345)
and the Company’s ADSs (each representing one-half of one ordinary
share) are traded on the Nasdaq Global Select Market (Ticker:
DBVT).
Viaskin and EPIT are trademarks of DBV
Technologies.
Investor Contact Anne PollakDBV
Technologies+1 857-529-2363anne.pollak@dbv-technologies.com
Media ContactAngela MarcucciDBV
Technologies+1 646-842-2393
angela.marcucci@dbv-technologies.com
DBV Technologies (EU:DBV)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
DBV Technologies (EU:DBV)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024